13 5月 2022 by admin in UncategorizedComments Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
12 5月 2022 by admin in UncategorizedComments Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
12 5月 2022 by admin in UncategorizedComments Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
10 5月 2022 by admin in UncategorizedComments Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma
09 5月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
09 5月 2022 by admin in UncategorizedComments Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
05 5月 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
27 4月 2022 by admin in UncategorizedComments Tempest Announces Private Placement Financing of $15 Million
19 4月 2022 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
